4-[2-(2(3H)-benzothiazolon-3-yl)ethoxy]benzaldehyde | 353283-40-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: 4-[2-(2(3H)-benzothiazolon-3-yl)ethoxy]benzaldehyde
• 英文别名: 4-[2-(2-Oxo-1,3-benzothiazol-3-yl)ethoxy]benzaldehyde
• CAS: 353283-40-6
• 化学式: C₁₆H₁₃NO₃S
• 分子量: 299.35
• InChiKey: ZGBUOTIEWXAFPF-UHFFFAOYSA-N

物化性质

• 熔点：
  118-120 °C(Solv: ethanol (64-17-5))
• 沸点：
  524.2±56.0 °C(Predicted)
• 密度：
  1.341±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  71.9
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-[2-(2(3H)-benzothiazolon-3-yl)ethoxy]benzaldehyde 在 palladium on activated charcoal 哌啶 、 氢氧化钾 、 氢气 、 溶剂黄146 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 乙醇 、 甲苯 为溶剂， 反应 72.0h， 生成 3-Ethoxy-3-oxo-2-{4-[2-(2-oxo-1,3-benzothiazol-3(2H)-yl)ethoxy]-benzyl}propanoic acid
  参考文献：
  名称：

  Novel 1,3-dicarbonyl compounds having 2(3H)-benzazolonic heterocycles as PPARγ agonists

  摘要：

  A series of 1,3-dicarbonyl compounds having 2(3H)-benzazolonic heterocycles has been synthesized and tested for PPAR gamma agonist activity. SAR were developed and revealed that 6-acyl-2(3H)-benzothiazolone derivatives with 1,3-dicarbonyl group were the most potent. IP administration of compound 22 exhibited comparable levels of glucose and triglyceride correction to PO administration of rosiglitazone in the oblob mouse studies. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.07.029
• 作为产物：
  描述：

  2-羟基苯并噻唑 、 4-(2-氯乙氧基)苯甲醛 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 以83%的产率得到4-[2-(2(3H)-benzothiazolon-3-yl)ethoxy]benzaldehyde
  参考文献：
  名称：

  Novel 1,3-dicarbonyl compounds having 2(3H)-benzazolonic heterocycles as PPARγ agonists

  摘要：

  A series of 1,3-dicarbonyl compounds having 2(3H)-benzazolonic heterocycles has been synthesized and tested for PPAR gamma agonist activity. SAR were developed and revealed that 6-acyl-2(3H)-benzothiazolone derivatives with 1,3-dicarbonyl group were the most potent. IP administration of compound 22 exhibited comparable levels of glucose and triglyceride correction to PO administration of rosiglitazone in the oblob mouse studies. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.07.029

文献信息

• Novel heterocyclic derivatives, preparation method and pharmaceutical compositions containing same
  申请人：——

  公开号：US20030040533A1

  公开（公告）日：2003-02-27

  Compounds of formula (I): 1 wherein: X represents an oxygen atom or a sulphur atom or a group CH 2 or 2 R 1 and R 2 represent a hydrogen atom, or a group as defined in the description, A represents an alkylene chain as described in the description, B is as defined in the description, R 3 and R 4 represent a hydrogen atom or a group as defined in the description, D represents an optionally substituted benzene, optionally substituted pyrazine, optionally substituted pyrimidine or optionally substituted pyridazine nucleus.

  式(I)的化合物：1其中：X代表氧原子、硫原子或CH2或2R1和R2代表氢原子，或如说明书中所定义的基团，A代表如说明书中所描述的亚烷基链，B如说明书中所定义，R3和R4代表氢原子或如说明书中所定义的基团，D代表可任选取代的苯环、可任选取代的吡嗪环、可任选取代的嘧啶环或可任选取代的吡啶嗪环。
• DERIVES D'AZOLES CONDENSES ET LEUR UTILISATION COMME AGENTS HYPOGLYCEMIANTS
  申请人：Les Laboratoires Servier

  公开号：EP1252150B1

  公开（公告）日：2003-06-04
• US6919362B2
  申请人：——

  公开号：US6919362B2

  公开（公告）日：2005-07-19
• Novel 1,3-dicarbonyl compounds having 2(3H)-benzazolonic heterocycles as PPARγ agonists
  作者：Elodie Blanc-Delmas、Nicolas Lebegue、Valérie Wallez、Véronique Leclerc、Saïd Yous、Pascal Carato、Amaury Farce、Caroline Bennejean、Pierre Renard、Daniel-Henri Caignard、Valérie Audinot-Bouchez、Pascale Chomarat、Jean Boutin、Nathalie Hennuyer、Katie Louche、Maria Carmen Carmona、Bart Staels、Luc Pénicaud、Louis Casteilla、Michel Lonchampt、Catherine Dacquet、Philippe Chavatte、Pascal Berthelot、Daniel Lesieur

  DOI：10.1016/j.bmc.2006.07.029

  日期：2006.11

  A series of 1,3-dicarbonyl compounds having 2(3H)-benzazolonic heterocycles has been synthesized and tested for PPAR gamma agonist activity. SAR were developed and revealed that 6-acyl-2(3H)-benzothiazolone derivatives with 1,3-dicarbonyl group were the most potent. IP administration of compound 22 exhibited comparable levels of glucose and triglyceride correction to PO administration of rosiglitazone in the oblob mouse studies. (c) 2006 Elsevier Ltd. All rights reserved.